Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Psychiatric Presentations in Adults With Autism Spectrum Disorder
NCT05015439Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Cannabidiol with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist at 6 weeks. Started Apr 2023; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05015439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015439.